european end-to-end CDMO company, pharma services
  • About us
    • History
    • Leaderships
    • Team
    • EU grants
    • Requests for Proposal
    • Sustainability – ESG
    • Bussines strategy
    • Quality policy
    • Virtual Tour
  • Services
    • Drug Substance Manufacturing
    • Fill & Finish
    • Gene to Vial: End-to-End Development
    • Process Development
    • Analytics 
    • Cell Line Development & Banking
  • Science Hub
    • Science News
    • Resources
  • News & Events
    • Press releases
    • Events
    • Content to download
  • Investors
    • Corporate documents
    • Shareholders and shares
    • Periodic reports
    • Current reports
    • Sustainability reports
    • Corporate governance at Mabion
    • Financial data
    • For Investors
    • Calendar
  • Contact us
    • Contact form
    • Contact for investors
    • Contact for media
    • Careers
  • EN
    • PL
  • Science News
  • Resources

Resources

Topic
All Analytics Antibody-drug conjugates Bioanalytics Biologics Biosimilars Biostatistics Cancer Cell culture Clinical trials Contamination Drug development Drug product Drug substance EMA FDA GMP Mabion Manufacturing Microbiology Partnership Proteins Regulatory Vaccines Veterinary biologics
Type
All Poster
bioprocess scale up

Bioprocess Scale-Up from Lab Scale to Commercial GMP Manufacturing 

Clinical trials, GMP, Manufacturing
Scaling Antibody Production for ADC Programs in Mabion manufacturing zone

Scaling Antibody Production for ADC Programs

Antibody-drug conjugates, Drug development, Manufacturing
innovative biologics 2026

Innovative Biologics Expected Approvals in 2026

Antibody-drug conjugates, Biologics, Bispecific antibody, Clinical trials, EMA, FDA, Monoclonal antibody, Vaccines
Declaration of the objectives and scope of the European Biotech Act

EU Biotech Act Ignites a New Wave of Biologics Partnerships

Biologics, Clinical trials, EMA, Regulatory
release testing for-biologics

Release Testing for Biologics – Regulatory Requirements for GMP Compliance

Analytics, Manufacturing
antibody drug-conjugates development

Breaking Barriers in Antibody-Drug Conjugates Development

Antibody-drug conjugates, Cancer
Previous 1 2 3 4 … 11 Next

Contact

Find out how we may support your business.

bd@mabion.eu

Mabion

gen. Mariana Langiewicza 60
95-050 Konstantynów Łódzki
Poland

+48 42 207 78 90

    Mabion
    • Privacy policy
    • Services
    • Investors
    • News&Events
    • Contact us

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Page Sitemap.

    Powered by

    Veneo